Huadong Medicine Co., Ltd
000963
주식 순위
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
주가
$3.89
시가총액
$6.83B
변동 (1일)
-2.22%
변동 (1년)
-30.58%
국가
CN
거래 Huadong Medicine Co., Ltd (000963)
카테고리
Healthcare
Huadong Medicine Co., Ltd (000963)의 매출
Jun 2026 기준 매출 TTM: $6.59B
Huadong Medicine Co., Ltd의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $6.59B입니다. 2024년에 회사는 $5.74B의 수익을 올렸으며 이는 2023년의 $5.74B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Huadong Medicine Co., Ltd의 수익 기록 (2001 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $6.59B | 5.71% |
| 2025 | $6.23B | 8.57% |
| 2024 | $5.74B | 0.04% |
| 2023 | $5.74B | 4.96% |
| 2022 | $5.47B | 0.54% |
| 2021 | $5.44B | 5.47% |
| 2020 | $5.16B | 1.29% |
| 2019 | $5.09B | 14.19% |
| 2018 | $4.46B | 4.21% |
| 2017 | $4.28B | 17.02% |
| 2016 | $3.66B | 9.25% |
| 2015 | $3.35B | 9.38% |
| 2014 | $3.06B | 10.99% |
| 2013 | $2.76B | 17.88% |
| 2012 | $2.34B | 32.41% |
| 2011 | $1.77B | 29.90% |
| 2010 | $1.36B | 18.60% |
| 2009 | $1.15B | 29.99% |
| 2008 | $881.72M | 32.65% |
| 2007 | $664.70M | 30.76% |
| 2006 | $508.34M | 17.77% |
| 2005 | $431.65M | 23.93% |
| 2004 | $348.31M | 23.94% |
| 2003 | $281.03M | 12.60% |
| 2002 | $249.58M | 9.48% |
| 2001 | $227.97M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| $29.24B | 343.74% |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 0.34% |
IN
|